SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-142977
Filing Date
2022-05-06
Accepted
2022-05-06 07:26:03
Documents
13
Period of Report
2022-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d355505d8k.htm   iXBRL 8-K 25839
2 EX-99.1 d355505dex991.htm EX-99.1 34247
  Complete submission text file 0001193125-22-142977.txt   187262

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akro-20220506.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20220506_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20220506_pre.xml EX-101.PRE 11253
7 EXTRACTED XBRL INSTANCE DOCUMENT d355505d8k_htm.xml XML 3367
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 22898834
SIC: 2834 Pharmaceutical Preparations